Clinical & Scientific

Insilico Medicine's AI-designed drug, ISM8969, enters human trials, targeting chronic neuroinflammation by crossing the elusive blood-brain barrier.

Rare complete responses in deadly pancreatic cancer hint at a powerful new synergy, but can Elicio Therapeutics secure the funding to prove its theory?

REV Exploration is deploying advanced 3D seismic tech in Montana, hunting for helium and natural hydrogen. It's a calculated move in a high-stakes global race.

A landmark grant and trial expansion signal a pivotal shift in Parkinson's research, blending genetic targeting, global collaboration, and digital health.

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

New data on ersodetug reveals a calculated strategy to conquer hyperinsulinism, balancing patient hope with the harsh realities of the biotech market.

High-grade results, including 170.9 g/t gold, are more than just numbers; they signal a strategic push to restart a historic mine and boost a region.

At BIO 2026, Israeli biotech Can-Fite seeks crucial partnerships for its late-stage cancer and inflammation drugs, built on a unique, safety-focused platform.

Paramount Gold's plan to revive the historic Sleeper Mine isn't just about digging. It's a savvy bet on high gold prices and innovative waste reprocessing.

ARMR Sciences reports a major breakthrough in the fight against overdose, but can a preventative vaccine truly turn the tide on the fentanyl crisis?

Milan-based WISE secured €30M to advance its stretchable neuro-implants, aiming to solve a critical dilemma in chronic pain treatment and neurotechnology.

A Swedish pharma company's trial is progressing faster than expected, but the real story is the potential paradigm shift for millions suffering from a neglected disease.

A new AU$481M deal with Everest Medicines brings a promising FSGS drug closer to 1M Asian patients, part of a larger, de-risked global strategy.

Verastem Oncology's new drug enters a pivotal trial for pancreatic cancer, targeting a notorious mutation with a novel dual-action mechanism.

With a novel non-hallucinogenic drug, Enveric Biosciences heads to the BIO convention seeking partners. Can its unique science secure its future?

A new approval in Abu Dhabi for NeOnc's NEO212 isn't just a clinical step; it's a strategic play in the high-stakes world of brain cancer therapy.

A pilot study shows light therapy improving memory in MCI patients, fueling the at-home neurotech boom. But can Vielight turn scientific promise into market reality?

A new program in Nevada is using breath-based tech to tackle first responder burnout. But can a simple device truly change the complex health of those who serve?

A major survey names Bonafide Health's products #1 in their class. We explore the strategy behind the headlines and what it signals for women's health.

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?